Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03758443
Registration number
NCT03758443
Ethics application status
Date submitted
19/11/2018
Date registered
29/11/2018
Date last updated
15/11/2022
Titles & IDs
Public title
Efficacy & Safety of TD-1473 in Ulcerative Colitis
Query!
Scientific title
A Phase 2b/3 Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled, Parallel-Group Set of Studies to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy With TD-1473 in Subjects With Moderately-to-Severely Active Ulcerative Colitis
Query!
Secondary ID [1]
0
0
2018-002136-24
Query!
Secondary ID [2]
0
0
0157
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
RHEA
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Ulcerative Colitis (UC)
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - TD-1473 Dose A
Treatment: Drugs - TD-1473 Dose B
Treatment: Drugs - TD-1473 Dose C
Treatment: Drugs - Placebo
Experimental: Active Treatment TD-1473 Dose A - Participants will be randomized to receive an oral daily dose of TD-1473. Responders will be re-randomized into the Phase 3 Maintenance portion of the study. Non-responders may participate in an extended induction.
Experimental: Active Treatment TD-1473 Dose B - Participants will be randomized to receive an oral daily dose of TD-1473. Responders will be re-randomized into the Phase 3 Maintenance portion of the study. Non-responders may participate in an extended induction.
Experimental: Active Treatment TD-1473 Dose C - Participants will be randomized to receive an oral daily dose of TD-1473. Responders will be re-randomized into the Phase 3 Maintenance portion of the study. Non-responders may participate in an extended induction.
Placebo Comparator: Placebo - Participants will be randomized to receive an oral daily dose of placebo. Participants who received Placebo (and were non-responders) may move to an extended induction. Subjects who are on placebo will be assigned to active TD-1473 for the extended induction (they will be blinded to dose).
Treatment: Drugs: TD-1473 Dose A
See Arm description
Treatment: Drugs: TD-1473 Dose B
See Arm description
Treatment: Drugs: TD-1473 Dose C
See Arm description
Treatment: Drugs: Placebo
See Arm description
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline in Total Mayo Score (tMS) at Week 8
Query!
Assessment method [1]
0
0
Total Mayo Score (tMS) was calculated as the sum of four components: rectal bleeding (0-3), stool frequency (0-3), physician's global assessment (0-3) and Mayo endoscopic subscore (0-3). tMS was reported as a 0-12 point score with 12 reflecting the highest severity.
Query!
Timepoint [1]
0
0
Baseline to Week 8
Query!
Primary outcome [2]
0
0
Phase 3 Maintenance: Number of Participants Who Demonstrated Clinical Remission by Adapted Mayo Score Components at Maintenance Week (mWeek) 44
Query!
Assessment method [2]
0
0
Clinical remission by Adapted Mayo score was defined based on Adapted Mayo score components within specific ranges: stool frequency score of 0 or 1, a rectal bleeding subscore of 0 and a Mayo endoscopy subscore of 0 or 1.
The Adapted Mayo score was the sum of three components: rectal bleeding, stool frequency, and Mayo endoscopic subscore, each measured on a scale of 0-3 with higher scores reflecting higher severity.
Participants with missing Week 44 values were imputed as non-responders.
Query!
Timepoint [2]
0
0
mWeek 44
Query!
Secondary outcome [1]
0
0
Number of Participants Who Demonstrated Clinical Remission by Adapted Mayo Score Components at Week 8
Query!
Assessment method [1]
0
0
Clinical remission by Adapted Mayo score was defined based on Adapted Mayo score components within specific ranges: stool frequency score of 0 or 1, a rectal bleeding subscore of 0 and a Mayo endoscopy subscore of 0 or 1.
The Adapted Mayo score was the sum of three components: rectal bleeding, stool frequency, and Mayo endoscopic subscore, each measured on a scale of 0-3 with higher scores reflecting higher severity.
Query!
Timepoint [1]
0
0
Week 8
Query!
Secondary outcome [2]
0
0
Phase 3 Maintenance: Number of Participants Who Demonstrated a Clinical Response by Adapted Mayo Score Components at mWeek 44
Query!
Assessment method [2]
0
0
Clinical response was defined as a reduction from baseline in adapted Mayo score of = 2 points and = 30% relative to baseline. It also required = 1 reduction in the rectal bleeding subscore or an absolute subscore = 1.
The Adapted Mayo score was the sum of three components: rectal bleeding, stool frequency, and Mayo endoscopic subscore, each measured on a scale of 0-3 with higher scores reflecting higher severity.
Participants with missing Week 44 values were imputed as non-responders.
Query!
Timepoint [2]
0
0
Baseline to mWeek 44
Query!
Secondary outcome [3]
0
0
Phase 3 Maintenance: Number of Participants Who Demonstrated Endoscopic Remission by Adapted Mayo Score Components at mWeek 44
Query!
Assessment method [3]
0
0
Endoscopic remission was defined as an endoscopic subscore = 1.
Endoscopic subscore was measured using scale of 0-3, where higher numbers reflected greater severity.
Query!
Timepoint [3]
0
0
mWeek 44
Query!
Secondary outcome [4]
0
0
Phase 3 Maintenance: Number of Participants Who Demonstrated Symptomatic Remission by Adapted Mayo Score Components at mWeek 44
Query!
Assessment method [4]
0
0
Symptomatic remission was defined as a stool frequency score = 1 and a rectal bleeding subscore of 0.
Stool frequency score and rectal bleeding score were each measured using scale of 0-3, where higher numbers reflected greater severity.
Participants with missing Week 44 values were imputed as non-responders.
Query!
Timepoint [4]
0
0
mWeek 44
Query!
Eligibility
Key inclusion criteria
- Is at least 18 years of age at screening
- Has a history of UC for at least 3 months prior to screening
- Has moderately-to-severely active UC, as defined by a Mayo endoscopic subscore of =2
points and an adapted Mayo score between 4 - 9 points inclusive
- Is corticosteroid-dependent or has demonstrated inadequate response, or intolerance to
conventional therapy (aminosalicylates, corticosteroids, immunomodulators) or
biologics
- Willing to use highly-effective methods of contraception during the study and for 7
days after the last dose
- Additional inclusion criteria apply
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Has symptoms suggestive of fulminant colitis, megacolon or intestinal perforation
- Likely to require surgery for UC or other major surgeries
- Has previously received / is currently receiving prohibited medications within
specified timeframe
- Is refractory to 3 biologics with =2 mechanisms of action
- Has a current bacterial, parasitic, fungal, or viral infection
- Has clinically significant abnormalities in laboratory evaluations
- Has had any prior exposure to an approved Janus kinase (JAK) inhibitor or potential
exposure to an investigational JAK inhibitor that was stopped due to intolerance or
lack of efficacy
- Additional exclusion criteria apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2/Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
11/03/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
20/10/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
239
Query!
Recruitment in Australia
Recruitment state(s)
QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Theravance Biopharma Investigational Site - South Brisbane
Query!
Recruitment hospital [2]
0
0
Theravance Biopharma Investigational Site - Woolloongabba
Query!
Recruitment hospital [3]
0
0
Theravance Biopharma Investigational Site - Malvern
Query!
Recruitment hospital [4]
0
0
Theravance Biopharma Investigational Site - Murdoch
Query!
Recruitment postcode(s) [1]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [2]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [3]
0
0
3144 - Malvern
Query!
Recruitment postcode(s) [4]
0
0
6150 - Murdoch
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Idaho
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Kansas
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kentucky
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Louisiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maryland
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Minnesota
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Nevada
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New York
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
North Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Pennsylvania
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
South Carolina
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Tennessee
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Texas
Query!
Country [20]
0
0
Bulgaria
Query!
State/province [20]
0
0
Sofiya
Query!
Country [21]
0
0
Bulgaria
Query!
State/province [21]
0
0
Pleven
Query!
Country [22]
0
0
Bulgaria
Query!
State/province [22]
0
0
Plovdiv
Query!
Country [23]
0
0
Bulgaria
Query!
State/province [23]
0
0
Ruse
Query!
Country [24]
0
0
Bulgaria
Query!
State/province [24]
0
0
Sliven
Query!
Country [25]
0
0
Bulgaria
Query!
State/province [25]
0
0
Sofia
Query!
Country [26]
0
0
Bulgaria
Query!
State/province [26]
0
0
Stara Zagora
Query!
Country [27]
0
0
Bulgaria
Query!
State/province [27]
0
0
Veliko Tarnovo
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
Ontario
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Champagne-ardenne
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Languedoc-roussillon
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Limousin
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Midi-pyrenees
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
NORD Pas-de-calais
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
PAYS DE LA Loire
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Picardie
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Rhone-alpes
Query!
Country [37]
0
0
Georgia
Query!
State/province [37]
0
0
Batumi
Query!
Country [38]
0
0
Georgia
Query!
State/province [38]
0
0
Tbilisi
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Baden-wuerttemberg
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Schleswig-holstein
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Thuringen
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Berlin
Query!
Country [43]
0
0
Greece
Query!
State/province [43]
0
0
Attica
Query!
Country [44]
0
0
Greece
Query!
State/province [44]
0
0
Crete
Query!
Country [45]
0
0
Greece
Query!
State/province [45]
0
0
Peloponnese
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Fejer
Query!
Country [47]
0
0
Hungary
Query!
State/province [47]
0
0
Hajdu-bihar
Query!
Country [48]
0
0
Hungary
Query!
State/province [48]
0
0
Tolna
Query!
Country [49]
0
0
Hungary
Query!
State/province [49]
0
0
Budapest
Query!
Country [50]
0
0
Israel
Query!
State/province [50]
0
0
Rehoboth
Query!
Country [51]
0
0
Israel
Query!
State/province [51]
0
0
Haifa
Query!
Country [52]
0
0
Israel
Query!
State/province [52]
0
0
Holon
Query!
Country [53]
0
0
Israel
Query!
State/province [53]
0
0
Jerusalem
Query!
Country [54]
0
0
Israel
Query!
State/province [54]
0
0
Nahariya
Query!
Country [55]
0
0
Israel
Query!
State/province [55]
0
0
Petah Tikva
Query!
Country [56]
0
0
Israel
Query!
State/province [56]
0
0
Rehovot
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Milano
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Catanzaro
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Pavia
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Aichi
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Chiba
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Fukuoka
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Gifu
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Gunma
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Hiroshima-ken
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Hiroshima
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Kanagawa
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Miyagi
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Nagano
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Oita
Query!
Country [71]
0
0
Japan
Query!
State/province [71]
0
0
Osaka Fu
Query!
Country [72]
0
0
Japan
Query!
State/province [72]
0
0
Osaka
Query!
Country [73]
0
0
Japan
Query!
State/province [73]
0
0
Saitama Ken
Query!
Country [74]
0
0
Japan
Query!
State/province [74]
0
0
Saitama
Query!
Country [75]
0
0
Japan
Query!
State/province [75]
0
0
Toyama
Query!
Country [76]
0
0
Japan
Query!
State/province [76]
0
0
Kumamoto
Query!
Country [77]
0
0
Japan
Query!
State/province [77]
0
0
Tokyo
Query!
Country [78]
0
0
Korea, Republic of
Query!
State/province [78]
0
0
Gangwon-do
Query!
Country [79]
0
0
Korea, Republic of
Query!
State/province [79]
0
0
Gyeonggi-do
Query!
Country [80]
0
0
Korea, Republic of
Query!
State/province [80]
0
0
Daegu
Query!
Country [81]
0
0
Korea, Republic of
Query!
State/province [81]
0
0
Seoul
Query!
Country [82]
0
0
Poland
Query!
State/province [82]
0
0
Dolnoslaskie
Query!
Country [83]
0
0
Poland
Query!
State/province [83]
0
0
Kujawsko-Pomorskie
Query!
Country [84]
0
0
Poland
Query!
State/province [84]
0
0
Lodzkie
Query!
Country [85]
0
0
Poland
Query!
State/province [85]
0
0
Lodzki
Query!
Country [86]
0
0
Poland
Query!
State/province [86]
0
0
Malopolskie
Query!
Country [87]
0
0
Poland
Query!
State/province [87]
0
0
Mazowieckie
Query!
Country [88]
0
0
Poland
Query!
State/province [88]
0
0
Pomorskie
Query!
Country [89]
0
0
Poland
Query!
State/province [89]
0
0
Slaskie
Query!
Country [90]
0
0
Poland
Query!
State/province [90]
0
0
Swietokrzyskie
Query!
Country [91]
0
0
Poland
Query!
State/province [91]
0
0
Wielkopolskie
Query!
Country [92]
0
0
Poland
Query!
State/province [92]
0
0
Zachodniopomorskie
Query!
Country [93]
0
0
Poland
Query!
State/province [93]
0
0
Szczecin
Query!
Country [94]
0
0
Portugal
Query!
State/province [94]
0
0
Coimbra
Query!
Country [95]
0
0
Portugal
Query!
State/province [95]
0
0
Guimarães
Query!
Country [96]
0
0
Portugal
Query!
State/province [96]
0
0
Leiria
Query!
Country [97]
0
0
Portugal
Query!
State/province [97]
0
0
Lisboa
Query!
Country [98]
0
0
Portugal
Query!
State/province [98]
0
0
Santa Maria Da Feira
Query!
Country [99]
0
0
Portugal
Query!
State/province [99]
0
0
Senhora da Hora
Query!
Country [100]
0
0
Portugal
Query!
State/province [100]
0
0
Viana Do Castelo
Query!
Country [101]
0
0
Portugal
Query!
State/province [101]
0
0
Vila Nova De Gaia
Query!
Country [102]
0
0
Romania
Query!
State/province [102]
0
0
Timis
Query!
Country [103]
0
0
Romania
Query!
State/province [103]
0
0
Bucuresti
Query!
Country [104]
0
0
Serbia
Query!
State/province [104]
0
0
Belgrade
Query!
Country [105]
0
0
Serbia
Query!
State/province [105]
0
0
Kragujevac
Query!
Country [106]
0
0
Serbia
Query!
State/province [106]
0
0
Nis
Query!
Country [107]
0
0
Serbia
Query!
State/province [107]
0
0
Subotica
Query!
Country [108]
0
0
Serbia
Query!
State/province [108]
0
0
Zrenjanin
Query!
Country [109]
0
0
Slovakia
Query!
State/province [109]
0
0
Prešovsky
Query!
Country [110]
0
0
Slovakia
Query!
State/province [110]
0
0
Nitra
Query!
Country [111]
0
0
Slovakia
Query!
State/province [111]
0
0
Šahy
Query!
Country [112]
0
0
South Africa
Query!
State/province [112]
0
0
Gauteng
Query!
Country [113]
0
0
Spain
Query!
State/province [113]
0
0
Barcelona
Query!
Country [114]
0
0
Spain
Query!
State/province [114]
0
0
Madrid
Query!
Country [115]
0
0
Spain
Query!
State/province [115]
0
0
Sevilla
Query!
Country [116]
0
0
Spain
Query!
State/province [116]
0
0
Valencia
Query!
Country [117]
0
0
Taiwan
Query!
State/province [117]
0
0
Kaohsiung
Query!
Country [118]
0
0
Taiwan
Query!
State/province [118]
0
0
Taichung
Query!
Country [119]
0
0
Taiwan
Query!
State/province [119]
0
0
Tainan
Query!
Country [120]
0
0
Taiwan
Query!
State/province [120]
0
0
Taipei
Query!
Country [121]
0
0
Ukraine
Query!
State/province [121]
0
0
Kiev City
Query!
Country [122]
0
0
Ukraine
Query!
State/province [122]
0
0
Kiev
Query!
Country [123]
0
0
Ukraine
Query!
State/province [123]
0
0
Poltava
Query!
Country [124]
0
0
Ukraine
Query!
State/province [124]
0
0
Transcarpathian
Query!
Country [125]
0
0
Ukraine
Query!
State/province [125]
0
0
Vinnytsya
Query!
Country [126]
0
0
Ukraine
Query!
State/province [126]
0
0
Chernivtsi
Query!
Country [127]
0
0
Ukraine
Query!
State/province [127]
0
0
Kharkiv
Query!
Country [128]
0
0
Ukraine
Query!
State/province [128]
0
0
Lviv
Query!
Country [129]
0
0
Ukraine
Query!
State/province [129]
0
0
Ternopil
Query!
Country [130]
0
0
Ukraine
Query!
State/province [130]
0
0
Vinnytsia
Query!
Country [131]
0
0
Ukraine
Query!
State/province [131]
0
0
Zaporizhzhya
Query!
Country [132]
0
0
Ukraine
Query!
State/province [132]
0
0
Úzhgorod
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Theravance Biopharma
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A Phase 2b/3 set of studies to evaluate the efficacy and safety of induction and maintenance
therapy with TD-1473 in subjects with moderately-to-severely active ulcerative colitis with
up to 60 weeks of treatment.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03758443
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Monitor
Query!
Address
0
0
Theravance Biopharma
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03758443
Download to PDF